Stryker Corporation $SYK Shares Acquired by Aviva PLC

Aviva PLC boosted its stake in Stryker Corporation (NYSE:SYK) by 6.4% in the 2nd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 255,869 shares of the medical technology company’s stock after purchasing an additional 15,369 shares during the period. Aviva PLC’s holdings in Stryker were worth $101,229,000 at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors also recently modified their holdings of the stock. Vanguard Group Inc. grew its stake in shares of Stryker by 1.1% in the first quarter. Vanguard Group Inc. now owns 33,059,964 shares of the medical technology company’s stock valued at $12,306,572,000 after buying an additional 361,136 shares in the last quarter. Price T Rowe Associates Inc. MD boosted its holdings in Stryker by 9.2% in the 1st quarter. Price T Rowe Associates Inc. MD now owns 12,131,218 shares of the medical technology company’s stock worth $4,515,847,000 after acquiring an additional 1,021,496 shares during the period. Goldman Sachs Group Inc. boosted its holdings in Stryker by 13.1% in the 1st quarter. Goldman Sachs Group Inc. now owns 2,252,895 shares of the medical technology company’s stock worth $838,640,000 after acquiring an additional 261,058 shares during the period. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC grew its position in Stryker by 4.2% in the first quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 2,086,960 shares of the medical technology company’s stock valued at $776,871,000 after acquiring an additional 83,954 shares in the last quarter. Finally, Charles Schwab Investment Management Inc. raised its stake in shares of Stryker by 1.5% during the first quarter. Charles Schwab Investment Management Inc. now owns 2,015,374 shares of the medical technology company’s stock valued at $750,223,000 after purchasing an additional 30,329 shares during the period. Institutional investors and hedge funds own 77.09% of the company’s stock.

Stryker Trading Up 0.5%

NYSE:SYK opened at $355.74 on Friday. The company has a market cap of $136.04 billion, a PE ratio of 47.12, a P/E/G ratio of 2.66 and a beta of 0.94. The business’s 50 day moving average is $374.63 and its two-hundred day moving average is $380.99. The company has a quick ratio of 1.06, a current ratio of 1.78 and a debt-to-equity ratio of 0.70. Stryker Corporation has a 52 week low of $329.16 and a 52 week high of $406.19.

Stryker (NYSE:SYK) last posted its quarterly earnings results on Thursday, October 30th. The medical technology company reported $3.19 earnings per share (EPS) for the quarter, beating the consensus estimate of $3.13 by $0.06. The business had revenue of $6.06 billion for the quarter, compared to analyst estimates of $6.04 billion. Stryker had a return on equity of 23.94% and a net margin of 12.25%.The business’s revenue was up 10.2% compared to the same quarter last year. During the same period in the prior year, the company posted $2.87 EPS. Stryker has set its FY 2025 guidance at 13.500-13.600 EPS. On average, analysts predict that Stryker Corporation will post 13.47 EPS for the current year.

Wall Street Analyst Weigh In

Several research analysts have recently weighed in on the stock. Needham & Company LLC upped their target price on shares of Stryker from $442.00 to $448.00 and gave the company a “buy” rating in a research note on Friday, August 1st. Barclays boosted their price objective on shares of Stryker from $443.00 to $453.00 and gave the stock an “overweight” rating in a report on Wednesday, October 22nd. Sanford C. Bernstein reissued an “outperform” rating on shares of Stryker in a research report on Monday. Weiss Ratings reaffirmed a “buy (b-)” rating on shares of Stryker in a research report on Wednesday, October 8th. Finally, Redburn Partners set a $420.00 price target on Stryker in a research note on Thursday, September 18th. Fourteen equities research analysts have rated the stock with a Buy rating and five have given a Hold rating to the company. Based on data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and an average target price of $433.37.

Insiders Place Their Bets

In related news, insider Viju Menon sold 500 shares of the stock in a transaction dated Monday, August 25th. The shares were sold at an average price of $390.61, for a total transaction of $195,305.00. Following the sale, the insider owned 12,511 shares in the company, valued at $4,886,921.71. This represents a 3.84% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, Director Ronda E. Stryker sold 276,173 shares of the firm’s stock in a transaction dated Thursday, November 6th. The stock was sold at an average price of $353.28, for a total transaction of $97,566,397.44. Following the completion of the transaction, the director directly owned 2,702,108 shares in the company, valued at $954,600,714.24. This represents a 9.27% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Insiders have sold 520,500 shares of company stock worth $184,803,065 over the last three months. 5.90% of the stock is owned by corporate insiders.

About Stryker

Stryker Corporation operates as a medical technology company. The company operates through two segments, MedSurg and Neurotechnology, and Orthopaedics and Spine. The Orthopaedics and Spine segment provides implants for use in total joint replacements, such as hip, knee and shoulder, and trauma and extremities surgeries.